# Mammoth Biosciences

> Mammoth Biosciences is a Brisbane, California biotechnology company co-founded by Nobel laureate Jennifer Doudna that develops ultracompact CRISPR systems for both in vivo gene-editing therapeutics and rapid molecular diagnostics. Its proprietary toolbox of small Cas enzymes (including Cas14 and CasΦ) powers therapeutic partnerships with Regeneron, Vertex and Bayer, while the DETECTR platform brings CRISPR-based disease detection out of the central lab.

- **Founded:** 2017
- **Headquarters:** Brisbane, California, United States
- **Founders:** Trevor Martin (Co-founder & CEO), Janice Chen (Co-founder, CSO & President of Research), Lucas Harrington (Co-founder), Jennifer Doudna (Co-founder & Chair of Scientific Advisory Board)
- **Team size:** ~210 employees
- **Products:** Ultracompact CRISPR Systems, DETECTR Platform, Therapeutic Pipeline, Protein Discovery Platform
- **Notable:** First demonstration of CRISPR-based detection of SARS-CoV-2 in patient samples (DETECTR)., Discovery and development of Cas14 and CasΦ - the smallest known CRISPR effectors at the time of publication., Over $465M raised across rounds.

## Products & services

- **Ultracompact CRISPR Systems** — A toolbox of novel, miniature Cas enzymes (Cas14, CasΦ and others) small enough to fit inside a single AAV vector, enabling in vivo gene editing in tissues that traditional CRISPR-Cas9 can't reach.
- **DETECTR Platform** — A CRISPR-based molecular diagnostic platform that searches a sample for nucleic acid signatures of disease. Used for SARS-CoV-2, infectious disease panels and biosurveillance.
- **Therapeutic Pipeline** — In vivo gene-editing programs - including MB-111 - targeting genetic and serious diseases.
- **Protein Discovery Platform** — A metagenomic engine that mines novel CRISPR-Cas proteins and effector tools from environmental DNA at scale.

## Achievements

- First demonstration of CRISPR-based detection of SARS-CoV-2 in patient samples (DETECTR).
- Discovery and development of Cas14 and CasΦ - the smallest known CRISPR effectors at the time of publication.
- Over $465M raised across rounds.
- Named to multiple lists of the world's most innovative biotech companies.

## Latest updates

- **2025-10** — Presented MB-111 in vivo gene-editing data at the 2025 ESGCT Congress.
- **2024-04** — Raised an additional $100M in venture funding to extend the therapeutic pipeline.
- **2023** — Expanded the Regeneron collaboration to additional in vivo targets.

## Links

- Website: https://mammoth.bio
- LinkedIn: https://www.linkedin.com/company/mammothbio
- Twitter/X: https://twitter.com/mammothbiosci
- Instagram: https://www.instagram.com/mammothbiosciences/
- Facebook: https://facebook.com/mammothbiosci/

---

Profile page: https://yespress.io/mammoth-biosciences
Published by YesPress — https://yespress.io
Last updated: 2026-05-19